News Pharma Industry

The call for waiver on vaccine patents has strong logic but weak legs

[ad_1]

Demonstrators holding banners to claim lower priced drugs for AIDS and Aam Aadmi Party workers protesting against Central governments directive on vaccination age bar.

Synopsis

India has been sending conflicting signals, resulting in ambiguity on its push for an international patent waiver on Covid-19 vaccines. But then, intellectual-property issues may not be the barrier to adequate availability of vaccines in India, and even if a waiver comes through, there may not be many takers for it.

Circa 2000. A devastating HIV-AIDS epidemic had engulfed continents. The previous year, 2.8 million people had succumbed to the virus, with sub-Saharan Africa bearing the brunt. Almost 19 million had perished from the time the outbreak started. The global count of newly infected HIV patients was a whopping 5.4 million.With the hope of reining in the virus fast ebbing, UK-based virologist Peter Piot, the executive director of a United Nations

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Special Offer on ET Prime

Subscribe to ET Prime – Get Flat 20% Off

View Plans

Special Offer on ET Prime

Subscribe to ET Prime – Get 25% Off

View Plans

Special Offer on ET Prime

Subscribe to ET Prime – Get 25% Off

View Plans

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

[ad_2]

Source link